1887
  1. Home
  2. Eurosurveillance
  3. Volume 26, Issue 20, 20/May/2021
  4. Article
Rapid communication Open Access
Like 0
Download

Abstract

We assess the feasibility of reaching the herd immunity threshold against SARS-CoV-2 through vaccination, considering vaccine effectiveness (VE), transmissibility of the virus and the level of pre-existing immunity in populations, as well as their age structure. If highly transmissible variants of concern become dominant in areas with low levels of naturally-acquired immunity and/or in populations with large proportions of < 15 year-olds, control of infection without non-pharmaceutical interventions may only be possible with a VE ≥ 80%, and coverage extended to children.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2021.26.20.2100428
2021-05-20
2024-11-25
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2021.26.20.2100428
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/26/20/eurosurv-26-20-1.html?itemId=/content/10.2807/1560-7917.ES.2021.26.20.2100428&mimeType=html&fmt=ahah

References

  1. Hall VJ, Foulkes S, Ayoub Saei A, Andrews N, Oguti B, Charlett A, et al. Effectiveness of BNT162b2 mRNA Vaccine Against Infection and COVID-19 Vaccine Coverage in Healthcare Workers in England, Multicentre Prospective Cohort Study (the SIREN Study). SSRN Electron J. 2021.  https://doi.org/10.2139/ssrn.3790399 
  2. Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD, et al. , CMMID COVID-19 Working Group, COVID-19 Genomics UK (COG-UK) Consortium. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science. 2021;372(6538):eabg3055.  https://doi.org/10.1126/science.abg3055  PMID: 33658326 
  3. Fine P, Eames K, Heymann DL. "Herd immunity": a rough guide. Clin Infect Dis. 2011;52(7):911-6.  https://doi.org/10.1093/cid/cir007  PMID: 21427399 
  4. World Health Organization (WHO). Feasibility Assessment of Measles and Rubella Eradication. Geneva: WHO; 2019. Available from: https://www.who.int/immunization/sage/meetings/2019/october/Feasibility_Assessment_of_Measles_and_Rubella_Eradication_final.pdf
  5. Kistler KE, Bedford T. Evidence for adaptive evolution in the receptor-binding domain of seasonal coronaviruses OC43 and 229e. eLife. 2021;10:e64509.  https://doi.org/10.7554/eLife.64509  PMID: 33463525 
  6. Belongia EA, Simpson MD, King JP, Sundaram ME, Kelley NS, Osterholm MT, et al. Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies. Lancet Infect Dis. 2016;16(8):942-51.  https://doi.org/10.1016/S1473-3099(16)00129-8  PMID: 27061888 
  7. Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD, et al. , CMMID COVID-19 Working Group, COVID-19 Genomics UK (COG-UK) Consortium. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science. 2021;372(6538):eabg3055.  https://doi.org/10.1126/science.abg3055  PMID: 33658326 
  8. Garcia-Beltran WF, Lam EC, St. Denis K, Nitido AD, Garcia ZH, Hauser BM, et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. medRxiv. 2021; 2021.02.14.21251704.  https://doi.org/http://dx.doi.org/10.1101/2021.02.14.21251704 
  9. Mattar S, Alvis-Guzman N, Garay E, Rivero R, García A, Botero Y, et al. Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence Among Adults in a Tropical City of the Caribbean Area, Colombia: Are We Much Closer to Herd Immunity Than Developed Countries? Open Forum Infect Dis. 2020;7(12):ofaa550.  https://doi.org/10.1093/ofid/ofaa550  PMID: 33354587 
  10. Hall VJ, Foulkes S, Charlett A, Atti A, Monk EJM, Simmons R, et al. , SIREN Study Group. SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN). Lancet. 2021;397(10283):1459-69.  https://doi.org/10.1016/S0140-6736(21)00675-9  PMID: 33844963 
  11. Harris RJ, Hall JA, Zaidi A, Andrews NJ, Dunbar K, Dabrera G. Impact of vaccination on household transmission of SARS-COV-2 in England. Available from: https://khub.net/documents/135939561/390853656/Impact+of+vaccination+on+household+transmission+of+SARS-COV-2+in+England.pdf/35bf4bb1-6ade-d3eb-a39e-9c9b25a8122a?t=1619601878136
  12. Arora RK, Joseph A, Van Wyk J, Rocco S, Atmaja A, May E, et al. SeroTracker: a global SARS-CoV-2 seroprevalence dashboard. Lancet Infect Dis. 2021;21(4):e75-6.  https://doi.org/10.1016/S1473-3099(20)30631-9  PMID: 32763195 
  13. Population ages 0-14 (% of total population). Data. Washington DC: World Bank. [Accessed: 4 Apr 2021]. Available from: https://data.worldbank.org/indicator/SP.POP.0014.TO.ZS
  14. Rodrigues EPS, Abreu IN, Lima CNC, da Fonseca DLM, Pereira SFG, Dos Reis LC, et al. High prevalence of anti-SARS-CoV-2 IgG antibody in the Xikrin of Bacajá (Kayapó) indigenous population in the brazilian Amazon. Int J Equity Health. 2021;20(1):50.  https://doi.org/10.1186/s12939-021-01392-8  PMID: 33509206 
  15. Amante A. Over half of people tested in Italy’s Bergamo have COVID-19 antibodies. The Jakarta Post. 2021. Available from: https://www.thejakartapost.com/news/2020/06/09/over-half-of-people-tested-in-italys-bergamo-have-covid-19-antibodies.html
  16. Hall V, Foulkes S, Charlett A, Atti A, Monk EJM, Simmons R, et al. Do antibody positive healthcare workers have lower SARS-CoV-2 infection rates than antibody negative healthcare workers? Large multi-centre prospective cohort study (the SIREN study), England: June to November 2020. medRxiv. 2021. 2021.01.13.21249642.  https://doi.org/http://dx.doi.org/10.1101/2021.01.13.21249642 
  17. Eggo RM, Dawa J, Kucharski AJ, Cucunuba ZM. The importance of local context in COVID-19 models. Nat. Comput. Sci.2021;1(1):6-8.  https://doi.org/10.1038/s43588-020-00014-7 
  18. Lovett S. UK secures 60 million additional Pfizer doses for autumn booster programme. The Independent. 2021. Available from: https://www.independent.co.uk/news/science/covid-vaccine-pfizer-doses-booster-b1839074.html
  19. Neil MF, Laydon D, Nedjati-Gilani G, Imai N, Ainslie K, Baguelin M, et al. Impact of non-pharmaceutical interventions (NPIs) to reduce COVID-19 mortality and healthcare demand. London: Imperial College London; 2020.  https://doi.org/http://dx.doi.org/10.25561/77482 
  20. Office for National Statistics (ONS). Coronavirus (COVID-19) Infection Survey, UK, 5 March 2021. Newport: ONS. 2021. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/coronaviruscovid19infectionsurveypilot/march2021
The potential for vaccination-induced herd immunity against the SARS-CoV-2 B.1.1.7 variant
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=David+Hodgson&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Hodgson David</a>, <a href="/search?value1=Stefan+Flasche&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Flasche Stefan</a>, <a href="/search?value1=Mark+Jit&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Jit Mark</a>, <a href="/search?value1=Adam+J+Kucharski&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Kucharski Adam J</a>, <a href="/search?value1=CMMID+COVID-19+Working+Group&option1=author&noRedirect=true" class="nonDisambigAuthorLink">CMMID COVID-19 Working Group</a></span>. The potential for vaccination-induced herd immunity against the SARS-CoV-2 B.1.1.7 variant. <a href="/content/ecdc">Euro Surveill.</a> 2021;26(20):pii=2100428. <a href="https://doi.org/10.2807/1560-7917.ES.2021.26.20.2100428" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2021.26.20.2100428</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 29 Apr 2021;&nbsp;&nbsp; <span class="generated">Accepted</span>: 20 May 2021 </span> </p>
/content/10.2807/1560-7917.ES.2021.26.20.2100428
/content/10.2807/1560-7917.ES.2021.26.20.2100428
Loading

Data & Media loading...

Supplementary data

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error